Breakfast Talk - Biotech Venture Investment: From Innovation to Entrepreneurial Financing | Peatixtag:peatix.com,2011:12019-11-02T09:14:51+08:00PeatixMITCS EventsBreakfast Talk - Biotech Venture Investment: From Innovation to Entrepreneurial Financingtag:peatix.com,2016:event-1893142016-09-16T07:30:00SGT2016-09-16T07:30:00SGTAbstract
The focal point for biotech venture investments have historically been
the US and Europe, with both locations making up the bulk of deals executed. In
recent years, China has emerged as the third largest hotbed in the global VC
rankings, with the opening of China’s economic floodgates resulting in a huge
inflow of investments and foreign capital into a market filled with
opportunities. Venture Capital plays a huge role in the development and growth
of companies, adding value and bringing them to greater heights. Yet the VC industry
is sometimes difficult to understand and gain insights into, and even more so
in China where there exists a complex and sometimes complicated business
landscape. We are fortunate to have Dr Chestor Ho who has been at the forefront
of the biotech VC industry over the past several decades help us provide
clarity and structured thoughts into this exciting and fast changing sector.
The Speaker
Dr Chestor Ho is currently
Chairman and CEO of Taifong Partners, a leading Asia/US Venture Capital Fund
dedicated to investing in the Healthcare Industry. With a combined experience
of over 50 years investment track record with offices in Boston, San Francisco
and Taipei, the Fund has made over 150 investments, and have successful exited
over 50 investments via an IPO or trade sale.
Dr Ho is currently an adjunct
professor at the National Chengchi University and teaches a class in “Venture
Capital and Entrepreneurship”. He has also taught Biochemical Engineering and
Biotechnology at State University of New York Buffalo and served on the Board
of Taiwan Venture Capital Association and Taiwan Biotech Industry Organization.
Dr Ho earned a MS and BS in
Chemical Engineering at Kansas State University (U.S.) and Chung Yuan
University (Taiwan). He earned his PhD in Chemical Engineering at MIT with a
minor in Biochemical Engineering under the guidance of Dr Daniel Wang and Ray
Baddour (a Founder of Amgen).